Lance Armstrong’s Era of Performance — Part II: Revisiting His Time Trial Wins
Authors:
- Hein F.M. LodewijkxHLHein F.M. Lodewijkx
- Arjan E.R. BosABArjan E.R. Bos
Open Access
- 1 January 2014
- journal article
- Published by Science and Education Publishing Co., Ltd. in American Journal of Sports Science and Medicine
- Vol. 2 (5) , 194-201
Abstract
This archival study (N = 100) compared Lance Armstrong's time trial wins to victories demonstrated by all former multiple Grand Tour winners (1949-1995; Coppi, Anquetil, Merckx, Hinault, Indurain) and by riders who won similar races in the three major European Grand Tours (Tour de France, Giro d'Italia, and Vuelta a España) from 2006 to 2013, who were either involved in doping affairs or not. Regression analyses yielded a non-significant M = 142 seconds difference between Armstrong vs. the aggregated other riders (ΔR 2 = .001, p = .20). The effect emerged after controlling for the influence of competition year (b =-12.23 s per year, ΔR2 = .045, p ≤ .001) and trial distances (b = 84.64 s per kilometer trial distance, ΔR 2 = .933, p ≤ .001) on the variation in riders' speed. Furthermore, Armstrong along with other riders who were suspended for doping use or who acknowledged having used doping in the 2006-2013 periods did not outperform riders who were not involved in doping affairs during the same years (M =-68 s, ΔR 2 = .01, p = .35). Findings disprove the argument from ignorance, a false logic which refers to the often heard opinion that cyclists' performances over time (including Armstrong's wins) are mainly determined by their use of increasingly potent doping aids. However, in contrast to this logic, the distances of the time trials constitute the main determinant of riders' performances rather than the year in which they competed, and riders engaged in doping affairs did not significantly outperform riders who were not.Keywords
This publication has 9 references indexed in Scilit:
- Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk–benefitBritish Journal of Clinical Pharmacology, 2013
- The evolving science of detection of ‘blood doping’British Journal of Pharmacology, 2012
- Some Empirical Notes on the Epo Epidemic in Professional CyclingResearch Quarterly for Exercise and Sport, 2011
- Effects of recombinant human erythropoietin in normal humansThe Journal of Physiology, 2011
- Tour de France, Giro, Vuelta, and classic European races show a unique progression of road cycling speed in the last 20 yearsJournal of Sports Sciences, 2010
- Speed Trends of Major Cycling Races: Does Slower Mean Cleaner?International Journal of Sports Medicine, 2010
- Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator modelsBehavior Research Methods, 2008
- ARE ATHLETES DOPED? SOME THEORETICAL ARGUMENTS AND EMPIRICAL EVIDENCEContemporary Economic Policy, 2007
- The Tour de France: a physiological reviewScandinavian Journal of Medicine & Science in Sports, 2003